Nike, FedEx, Skillz, Ford and more

Take a look at some of the major engines on the premarket:

Nike (NKE) – Nike was 14 cents a share above estimates, with quarterly earnings of 90 cents a share. However, the athletic apparel and footwear company’s revenue was below analyst projections, and its full-year revenue outlook was also below estimates. Nike said North American revenue was hit by port-related issues that delayed shipments for up to three weeks. Nike shares fell 3.2% in premarket trading.

FedEx (FDX) – FedEx reported quarterly earnings of $ 3.47 per share, beating the consensus estimate of $ 3.23 per share. Revenues also beat expectations. FedEx’s average revenue per package for its ground service increased 11% as it continues to benefit from the pandemic-related surge in e-commerce orders. Its shares were up 4% in premarket stocks.

Skillz (SKLZ) – Skillz fell 7% in premarket stock after the mobile games company announced a public offering of 32 million shares. The offering was priced at $ 24 a share, with Skillz selling 17 million shares and certain shareholders selling the remainder. Skillz said it would use the proceeds for general corporate purposes.

AstraZeneca (AZN) – AstraZeneca’s Covid-19 vaccine received endorsement from Canadian regulator Health Canada, which joined European countries in saying the vaccine is not linked to an increase in blood clots. Countries that had temporarily stopped using the vaccine have now resumed giving injections.

Hartford Financial (HIG) – The financial services company said it is “carefully considering” a proposed acquisition of insurance company Chubb (CB) for $ 65 a share or more than $ 23 billion. Hartford shares rose 18.7% on Thursday following news of the offering, although it is down about 1.4% in premarket trading.

Ollie’s Bargain Outlet (OLLI): Ollie’s pace is estimated at 14 cents a share, with quarterly earnings of 97 cents a share. The discount retailer’s revenue also beat Wall Street forecasts. Comparable store sales increased 8.8%, beating FactSet’s consensus forecast of a 3.2% increase. Ollie’s stock gained 4.6% in premarket trading.

Enphase (ENPH), SolarEdge Technologies (SEDG) – Susquehanna Financial upgraded both alternative energy stocks to “positive” from “neutral”, based on an anticipated expansion of solar installations in the coming years and the strength of the two companies in the sector. residential. . Enphase was up 3.3% in the pre-market phase, while SolarEdge gained 2.1%.

Ford Motor (F) – Ford shares rose 2.5% in premarket trading after Barclays raised shares to “overweight” from “equal weight” and raised its target share price to $ 16 per share from $ 9. Barclays is encouraged by the development of Ford’s electric vehicle strategy, among other factors.

Coherent (COHR) – The laser technology company remains on guard, as it considers the takeover bids for Lumentum (LITE) and II-VI (IIVI). Coherent first struck a deal to be acquired by Lumentum in January, but has received eight subsequent offers and revised offers since then.

Molson Coors (TAP) – The brewer’s shares fell 2.3% in pre-market share after Deutsche Bank added it to its list of “short-term selling catalysts.” Deutsche Bank said the call is based on short-term concerns, including a material impact on first-quarter results from adverse February weather in Texas.

Petco Health (WOOF) – The pet supplies retailer was upgraded to “buy” from “neutral” on Bank of America Securities, saying Petco’s fourth-quarter and 2021 results were above expectations. The shares were up 2.8% in pre-market trading after losing 3.8% in Thursday’s trading.

Hims & Hers Health (HIMS) – Hims & Hers Health shares fell 3.3% in the previous market after the telehealth company reported a net quarterly loss of $ 3.1 million, although it was less than the loss of $ 12.4 million reported a year earlier. However, revenue was higher than anticipated and total revenue increased by 80% for 2020.

Sarepta Therapeutics (SRPT): The drugmaker’s shares rose 5.4% in premarket trading after it reported optimistic results in a trial that included an experimental treatment for muscular dystrophy.


Source link